INTRODUCTION
Blood transfusion plays an essential role in modern medicine and surgery. Loss of blood, whether occurring spontaneously or as a result of trauma, can be rectified by the transfusion of whole blood or of concentrated red cells, a practice so well established as to be taken almost for granted. More recently, transfusion of particular components of blood has been introduced as part of the management of a wide variety of diseases. Indeed, whereas the usage of red cells has been increasing slowly, the demand for many of these other blood components has shown a dramatic upsurge in recent years. This upward trend applies particularly to platelet concentrates, fresh frozen plasma, and various plasma products, especially Factor Vill, albumin and certain immunoglobulins. This development has placed additional burdens on the Blood Transfusion Service which is responsible for the production of components from donated blood. The huge increase in demand for blood components means that a high proportion of blood collected is now processed at the Transfusion Centre laboratories. The Table summarises the issues of blood and the major blood components to hospitals in the Province from 1974-84. It can be seen that, although blood donations have not been increasing during the past 6-7 years, the usage of most blood components has increased dramatically during the same period. The exception is cryoprecipitate, the usage of which has decreased as this product is gradually replaced by freeze-dried concentrates of Factor VIII for the treatment of haemophilia A. As in the rest of the UK, a proportion of the Factor Vill concentrate used in the Province has had to be imported, and the sudden increase in supply during the past year reflects a determined drive to become selfsufficient in this product. FUTURE DEVELOPMENTS As indicated above, apheresis procedures have been used hitherto on a small scale, being restricted to highly selected donors. This is likely to change in the near future as the demand for blood components (e.g. platelet concentrates and certain plasma products) normally collected from random donors, continues to increase rapidly. Since the demand for red cells is growing much more slowly, it seems logical to augment supplies of these non -red cell products by the adoption of apheresis procedures on a proportion of the normal blood donor population. Until recently, the methods available have been too cumbersome, slow and costly to allow apheresis to be used on a large scale. Devices are now being produced which make this much more feasible and have already been used for the collection of large volumes of platelets and plasma in some centres. 4 It is likely that the demand for blood components will continue to increase at least in the short-term. Eventually, it is quite possible, as developments in genetic engineering enable some of these products to be synthesised, that the requirement for blood components of human origin will decrease.
